Quarterly Update - Q2 2026 Peptide News
The second quarter of 2026 has been a bustling period for peptide drug development, with continued growth in obesity and metabolic health and new developments in oncology and pain management. We’ve highlighted advancements spanning Phase 2/3 data in chronic weight management as well as targeted peptide treatments tackling oncology, rare bone disorders, and chronic inflammation.
Read more...